SCHEMBL10043899

SCHEMBL10043899

CCc1cccc(NC(=O)c2ccc(C)c(-c3cc4cnc(C)cc4n(C)c3=O)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.46
CHRNB2 P17787 2/20 0.45
CHRNB4 P30926 2/20 0.45
CHRNA3 P32297 2/20 0.45
CHRNA4 P43681 2/20 0.45
MAPK13 O15264 1/20 0.42
RAF1 P04049 1/20 0.42
PDGFRA P16234 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
MAPK12 P53778 1/20 0.42
KCNH2 Q12809 1/20 0.42
MAPK11 Q15759 1/20 0.42
SYK P43405 1/20 0.41
FGFR1 P11362 1/20 0.41
SRC P12931 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043912 0.85 NPC1 (0.51) MAPK14MAPK13RAF1PDGFRAMAPKAPK2
SCHEMBL10043891 0.85 SYK (0.43) MAPK14MAPK13RAF1PDGFRAMAPKAPK2
SCHEMBL10043906 0.84 MAPK14 (0.45) MAPK14MAPK13RAF1PDGFRAMAPKAPK2
SCHEMBL10043904 0.83 MTOR (0.53) MAPK14MAPK13RAF1PDGFRAMAPKAPK2
SCHEMBL10043926 0.83 MAPK14 (0.45) MAPK14MAPK13RAF1PDGFRAMAPKAPK2
SCHEMBL502061 0.83 CNR1 (0.48) MAPK14SRCPOLBNPC1
SCHEMBL10043916 0.82 MAPK14 (0.47) MAPK14MAPK13RAF1PDGFRAMAPKAPK2
SCHEMBL10043897 0.82 ALDH1A1 (0.59) MAPK14MEN1KMT2ANPC1
SCHEMBL10043919 0.82 NPC1 (0.50) MAPK14MAPK13RAF1PDGFRAMAPKAPK2
SCHEMBL10043900 0.82 NPC1 (0.46) MAPK14MAPK13RAF1PDGFRAMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPK14 117/4885CHRNB2 1378/4885CHRNB4 1174/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPK14 117/4885CHRNB2 1378/4885CHRNB4 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.